Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.

Karim Fizazi,Gero Kramer,Jean-Christophe Eymard,Johann S. de Bono,Cora N. Sternberg,Bertrand F. Tombal,Daniel Castellano,Christian Wülfing,Michail Liontos,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Asgerour Sverrisdottir,Christine Theodore,Susan Feyerabend,Carole Helissey,Pascaline Picard,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Ronald de Wit

Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.

2020

16Background: The CARD NCT02485691 study reported superior rPFS and OS with CBZ vs abiraterone or enzalutamide in patients with mCRPC who progressed on docetaxel and within 12 months on a previous ...

Keywords:

Prostate cancer
Cabazitaxel
Castration
Oncology
Quality of life
Physical therapy
Abiraterone
Internal medicine
Docetaxel
Enzalutamide
Medicine
castration resistant
health related quality of life
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations